Using a high-end technology platform interfacing biology with robotics, the HTS team runs several target-based screens to identify hits for different therapeutic conditions. Equipped with completely automated robotics with a scalable software package, HTS has identified more than 10,000 hits. These hits are used to enhance the internal drug discovery pipeline. Several scaffolds are emerging which have shown efficacy in disease group models.
The HTS group has further added on a “High Content Screening Platform” for evaluation of the active scaffolds on cell signaling pathways. Interactions with the disease teams to provide mechanistic solutions on these scaffolds are providing value addition for lead selection on several therapeutic targets.
High Content Screening offers several advantages:
- The ability to multiplex multi-parameter assays
- Achieve fast image acquisition and high signal-to-noise ratios.
- Analyze cells using either fluorescent markers or Brightfield imaging.
- Analyze cells in their physiological state using an automated integrated system.
- Novel targets and assay formats can be developed for screening (96-well based)
- Large range of magnifications for imaging all types of mammalian cell-based assays
- Applications of HCS
- Evaluation of hits
- Hit to Lead identification
- Defining mechanism of action
- Prioritization of HITS
.jpg)
Selected publications:
- Amit Khanna, K Mahalingam, Debarshi Chakrabarti and Giridharan Periyasamy. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cellular and Molecular Biology Letters, 2011, 16: 101-113.
- Sunil V Mali, M. Himaja, Amit Khanna, Giridharan Periyasamy and Apparao Satyam. Synthesis and evaluation of conjugates of Non-steroidal anti-inflammatory drugs (NSAIDs) with Valproic acid for antiproliferative properties and apoptosis induction, Journal of Pharmacy Research, 2011, 4(7), 2136-2139.